Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte
Will ViaCyte's Encaptra Cell Delivery System 'Cure' Type 1 Diabetes? | Insulin Nation
ViaCyte | Regenerative Medicine Therapies for Diabetes
Stem Cell Implants Could Cure Diabetes | Healthcare Packaging
ViaCyte and Gore Expand Collaboration to Develop Novel Membrane and Device Technologies that Enhance Delivery of Cell Replacement Therapies for Diabetes
ViaCyte (@ViaCyte) / Twitter
Stem cell biotech ViaCyte staffs up CSO role to drive diabetes treatments | Fierce Biotech
ViaCyte treats first patients in PEC-Direct stem cell trial for type 1 diabetes | The Stem Cellar
ViaCyte reports positive cell replacement result for diabetes
Type 1 Diabetes Cures in Spotlight with Vertex Deal
JDRF Applauds the Small Business Innovative Research Award to ViaCyte
Vertex to acquire ViaCyte, targeting type 1 diabetes
ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes | Bain Capital
Product Pipeline for Insulin-Requiring Diabetes Treatments
ViaCyte and CRISPR Introduce New Stem Cell Therapy for Type 1 Diabetes
ViaCyte Advances Cell Replacement Therapy for High Risk Type 1 Diabetes | The Stem Cellar
Xconomy: ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics
ViaCyte (@ViaCyte) / Twitter
Stem Cell-derived Treatment One Step Closer to Type 1 Diabetes Cure
Product Pipeline for Insulin-Requiring Diabetes Treatments
ViaCyte | Regenerative Medicine Therapies for Diabetes
Vertex buys ViaCyte for $320M, clearing out T1D competition
ViaCyte | Regenerative Medicine Therapies for Diabetes
Diabetes space continues to run hot with Vertex/ViaCyte deal - MM+M
ViaCyte's Sweet Three-Pronged Attack against Type 1 Diabetes
